New drug combo trial targets Hard-to-Treat breast and ovarian cancers

NCT ID NCT06188520

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will take part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD8421 (a CDK2 inhibitor) alone or in combination with camizestrant, ribociclib, palbociclib, or abemaciclib
What this could lead to: If successful, this could lead to a new treatment option for people with advanced ER+ breast cancer or high-grade ovarian cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1/2a) trial, so the drug may not work or may cause unexpected side effects. It is also only for specific cancer types and may not benefit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

estrogen-receptor positive breast cancer hormone receptor-positive breast cancer ovarian serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER+ / HER2- ADVANCED BREAST CANCER HIGH-GRADE SEROUS OVARIAN CANCER (HGSOC)

Contacts and locations

Locations

Research Site
RECRUITING

St Louis, Missouri, 63141, United States
Research Site
RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
RECRUITING

Nashville, Tennessee, 37201, United States
Research Site
RECRUITING

Houston, Texas, 77030, United States
Research Site
RECRUITING

East Melbourne, 3002, Australia
Research Site
RECRUITING

Seoul, 03722, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea
Research Site
RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

Pamplona, 31005, Spain
Research Site
RECRUITING

Valencia, 46010, Spain
Research Site
RECRUITING

Cambridge, CB2 0XY, United Kingdom
Research Site
RECRUITING

Leeds, LS9 7TF, United Kingdom
Research Site
RECRUITING

London, EC1A 7BE, United Kingdom
Research Site
RECRUITING

Manchester, M20 4BX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.